Does the NeoGenomics (NEO) CEO have indirect share ownership reported in this filing?

Yes. The filing shows 18,900 NeoGenomics common shares held indirectly through the Amended and Restated Anthony P. Zook Living Trust. This trust holding is reported as indirect ownership, supplementing his directly held shares and giving a fuller picture of his total reported equity exposure.

NeoGenomics (NEO) CEO exercises RSUs and uses shares to cover taxes

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

NeoGenomics Inc. Chief Executive Officer Anthony P. Zook exercised equity awards and settled related taxes using shares. On April 1, 2026, he converted 140,498 restricted stock units into the same number of common shares at a $0.00 exercise price. Of these, 45,453 common shares were withheld to cover tax obligations, leaving 133,111 common shares held directly after the transactions, plus 18,900 shares held indirectly through the Amended and Restated Anthony P. Zook Living Trust. He also continues to hold substantial stock options and restricted stock units granted in 2025 and 2026 that vest ratably over three years and have premium exercise prices based on 110% of the stock’s closing prices on the respective grant dates.

Insider Trade Summary

140,498 shares exercised/converted

Mixed 9 txns

Insider Zook Anthony P.

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	140,498	$0.00	--
Exercise	Common Stock	140,498	$0.00	--
Tax Withholding	Common Stock	45,453	$0.00	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Restricted Stock Unit	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Unit — 280,998 shares (Direct); Common Stock — 178,564 shares (Direct); Stock Option (Right to Buy) — 8,353 shares (Direct); Common Stock — 18,900 shares (Indirect, Amended and Restated Anthony P. Zook Living Trust)

Footnotes (1)

On April 1, 2025, Mr. Zook was granted 421,496 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. Once vested, the shares of common stock are not subject to expiration. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%. On April 1, 2025, Mr. Zook was granted 729,927 stock options. The options vest ratably over the first three anniversary dates of the grant date. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 27, 2026 and multiplied by 110%. On March 1, 2026, Mr. Zook was granted 675,676 stock options. The options vest ratably over the first three anniversary dates of the grant date. On March 1, 2026, Mr. Zook was granted 406,918 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

Key Figures

RSUs exercised: 140,498 shares Shares withheld for taxes: 45,453 shares Direct common shares after transactions: 133,111 shares +5 more

8 metrics

RSUs exercised 140,498 shares Restricted stock units converted to common stock on April 1, 2026

Shares withheld for taxes 45,453 shares Common shares used for tax-withholding disposition on April 1, 2026

Direct common shares after transactions 133,111 shares Direct NeoGenomics common stock held by CEO after April 1, 2026

Indirect trust shares 18,900 shares Common stock held via Amended and Restated Anthony P. Zook Living Trust

2026 RSU grant 406,918 units Restricted stock units granted March 1, 2026, vesting over three years

2026 option grant 675,676 options at $10.81 Premium-price stock options expiring March 1, 2036

2025 option grant 729,927 options at $10.44 Premium-price stock options expiring April 1, 2035

2025 RSU grant 421,496 units Restricted stock units granted April 1, 2025, vesting over three years

Key Terms

Restricted Stock Unit, tax-withholding disposition, premium-price stock option, vest ratably, +1 more

5 terms

Restricted Stock Unit financial

"On April 1, 2025, Mr. Zook was granted 421,496 restricted stock units."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

tax-withholding disposition financial

"Payment of exercise price or tax liability by delivering securities."

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

premium-price stock option financial

"This stock option was granted as a premium-price stock option."

vest ratably financial

"The restricted stock units vest ratably over the first three anniversary dates."

Amended and Restated Anthony P. Zook Living Trust financial

"nature_of_ownership: Amended and Restated Anthony P. Zook Living Trust"

Form 4 Insider Transactions: What Each Field Means →

04/03/2026 - 04:38 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zook Anthony P.

(Last)

(First)

(Middle)

9490 NEOGENOMICS WAY

(Street)

FORT MYERS

FLORIDA

33912

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEOGENOMICS INC [ NEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/01/2026		M		140,498	A	$0	178,564	D
Common Stock	04/01/2026		F		45,453	D	$0	133,111	D
Common Stock								18,900	I	Amended and Restated Anthony P. Zook Living Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	$0	04/01/2026		M			140,498	⁽¹⁾	⁽²⁾	Common Stock	140,498	$0	280,998	D
Stock Option (Right to Buy)	$14.82							08/10/2024	08/10/2033	Common Stock	8,353		8,353	D
Stock Option (Right to Buy)	$13.71							06/01/2025	06/01/2034	Common Stock	8,672		8,672	D
Stock Option (Right to Buy)	$10.44⁽³⁾							⁽⁴⁾	04/01/2035	Common Stock	729,927		729,927	D
Stock Option (Right to Buy)	$10.81⁽⁵⁾							⁽⁶⁾	03/01/2036	Common Stock	675,676		675,676	D
Restricted Stock Unit	$0							⁽⁷⁾	⁽²⁾	Common Stock	406,918		406,918	D

Explanation of Responses:

1. On April 1, 2025, Mr. Zook was granted 421,496 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

2. Once vested, the shares of common stock are not subject to expiration.

3. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%.

4. On April 1, 2025, Mr. Zook was granted 729,927 stock options. The options vest ratably over the first three anniversary dates of the grant date.

5. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 27, 2026 and multiplied by 110%.

6. On March 1, 2026, Mr. Zook was granted 675,676 stock options. The options vest ratably over the first three anniversary dates of the grant date.

7. On March 1, 2026, Mr. Zook was granted 406,918 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

Remarks:

	/s/ Ali Olivo, Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did NeoGenomics (NEO) CEO Anthony P. Zook report?

Anthony P. Zook exercised 140,498 restricted stock units into common shares on April 1, 2026. This was a compensation-related equity conversion rather than an open-market purchase, reflecting vesting of prior awards rather than new cash investment in NeoGenomics stock.

How many NeoGenomics (NEO) shares were withheld for taxes in this Form 4?

NeoGenomics reported that 45,453 common shares were used for tax withholding tied to the CEO’s RSU vesting. This F-code transaction represents payment of tax obligations in shares, not an open-market sale, and is a routine aspect of equity compensation settlements.

How many NeoGenomics (NEO) shares does the CEO hold directly after the transactions?

After the April 1, 2026 equity transactions, Anthony P. Zook holds 133,111 NeoGenomics common shares directly. This figure reflects the net balance after exercising 140,498 RSUs and using 45,453 shares to satisfy tax obligations associated with the vesting of those restricted stock units.

What stock options for NeoGenomics (NEO) does the CEO retain after this Form 4?

The CEO retains several stock option positions, including options over 729,927 and 675,676 NeoGenomics shares with exercise prices of $10.44 and $10.81. These premium-price options expire in 2035 and 2036 and vest ratably over three years from their grant dates.

What new restricted stock units are outstanding for the NeoGenomics (NEO) CEO?

Footnotes state that on March 1, 2026 Anthony P. Zook was granted 406,918 restricted stock units. These RSUs convert into common shares at a $0.00 exercise price and vest ratably over the first three anniversaries of the March 1, 2026 grant date.